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Abstract. The aim of this review paper is to compare the potential of various techniques developed for
production of homogenous, stable liposomes. Traditional techniques, such as Bangham, detergent
depletion, ether/ethanol injection, reverse-phase evaporation and emulsion methods, were compared
with the recent advanced techniques developed for liposome formation. The major hurdles for scaling up
the traditional methods are the consumption of large quantities of volatile organic solvent, the stability
and homogeneity of the liposomal product, as well as the lengthy multiple steps involved. The new
methods have been designed to alleviate the current issues for liposome formulation. Dense gas liposome
techniques are still in their infancy, however they have remarkable advantages in reducing the use of
organic solvents, providing fast, single-stage production and producing stable, uniform liposomes.
Techniques such as the membrane contactor and heating methods are also promising as they eliminate
the use of organic solvent, however high temperature is still required for processing.
KEY WORDS: dense gas technology; drug delivery; liposomes; nano-particles; phospholipid.
INTRODUCTION
Liposomes are formed when phospholipids spontaneous-
ly self-assemble into vesicles in the presence of water,
producing an aqueous medium surrounded by a lipid
membrane. Liposomes are excellent carrier systems for a
variety of applications and are particularly ideal for drug
delivery to the body due to the similarity to natural cells. The
therapeutic index of drugs can be increased through incorpo-
ration into liposomes, which can act as a non-toxic, biode-
gradable system for solubilising drugs which have low
aqueous solubility; protect rapidly degrading drugs from
breakdown and consequently increase the drug residence
time in the body; and also decrease drug toxicity (1). Delivery
of drugs using liposomes also reduces the accumulation of
drugs in sensitive tissues; alters the biodistribution and
controls the release of an incorporated drug, therefore
improving bioavailability; as well as targets the drug to
speciﬁc tissue (1).
The stability and circulatory time in the bloodstream of
liposomal formulations can be improved by addition of
cholesterol and biocompatible, hydrophilic polymers with a
ﬂexible main chain, such as poly(ethylene glycol) (2,3).
Cholesterol is incorporated into the lipid bilayer and
decreases any bilayer packing defects, therefore the structure
is less prone to absorption and penetration by opsonins than
vesicles with loosely packed bilayers (4). The structure of a
liposome that has been stabilised through incorporating
polymer into the particle surface is depicted in Fig. 1, with
the polymer able to sterically hinder blood components from
interacting with the liposome surface. A sufﬁciently long
circulatory time in the bloodstream is required for a drug or
carrier to ﬁnd its target, thus the major medical application of
sterically stabilised liposomes is in cancer therapy (5).
A manufacturing method is desirable to formulate
liposomes with high entrapment efﬁciency, narrow size
distribution, long-term stability and protective properties.
The hurdles for broad use of liposomes for human applica-
tions are low stability, high cost for large scale production,
toxicity of organic residue, and low entrapment efﬁciency.
Pharmaceutical companies are eager to develop a technique
to address the above issues. In this article, an overview of
techniques used for manufacturing liposomes is provided.
The advantages and drawbacks of each method, as well as its
potential for bulk production of liposomes, are described and
references have been provided for readers interested in
acquiring further information for each process.
BACKGROUND OF METHODS
Conventional Techniques for the Synthesis of Liposomes
There are a wide variety of conventional techniques that
can be used to produce liposomal formulations, including
Bangham, detergentdepletion, ether/ethanol injection, reverse-
phaseevaporationandemulsionmethods(6,7). All methods for
producing liposomes require lipids to be combined by some
means with an aqueous phase. The conventional methods
generally involve a lipid solution being produced using an
1530-9932/08/0300-0798/0 # 2008 American Association of Pharmaceutical Scientists 798
AAPS PharmSciTech, Vol. 9, No. 3, September 2008 (# 2008)
DOI: 10.1208/s12249-008-9097-x
1School of Chemical Sciences and Engineering, The University of
New South Wales, Sydney, New South Wales 2052, Australia.
2School of Chemical and Biomolecular Engineering, The University
of Sydney, Sydney, New South Wales 2006, Australia.
3To whom correspondence should be addressed. (e-mail: fdehghani
@usyd.edu.au)organic solvent prior to dispersion in the aqueous phase. The
use of a volatile organic solvent may affect the chemical
structure of an entrapped chemical and also contribute to the
toxicity and stability of the liposome (8).
Bangham Method
The Bangham method is also known as the hand shaken
or thin ﬁlm hydration method and is one of the most widely
used techniques for the formation of liposomes (6,9,10). The
process involves the dissolution of lipids in an organic phase,
followed by the removal of the organic solvent, usually via
evaporation, to form a lipid ﬁlm. The solvent removal stage is
time-consuming since it often requires several hours exposure
to high vacuum. The ﬁnal step is the dispersion or hydration
of the lipid ﬁlm with an aqueous media, carried out in
conjuction with agitation to detach the swelling lamellae from
the vessel surface and form sealed spherical structures.
Liposomes produced via the Bangham method are often
several microns in size. The Bangham method is one of the
simplest methods for liposome formation, however it has
limited use due to low entrapment efﬁciency, difﬁculty in
removing organic solvent, homogenisation and small scale
production.
Ran and Yalkowsky produced liposomes using the thin
ﬁlm method by replacing the organic solvent with halothane,
an o n - ﬂammable, non-carcinogenic inhalation anaesthetic
(11). Liposomes encapsulating an anti-tumour drug, both
with and without polymer incorporation, were formed. After
homogenisation by sonication at 45°C, the liposomes ranged
in size from 170–230 nm. High encapsulation efﬁciency and
liposome stability were achieved using this method; with
more than 90% of the drug remaining inside the liposomes
after 3 months of storage at 4°C.
Detergent Depletion Method
The detergent depletion method is a mild process for
production of a wide variety of vesicle types and highly
homogeneous liposomes. The method is based on the
formation of detergent-lipid micelles, followed by the remov-
al of the detergent to form liposomes. Detergent-lipid
micelles can be formed by either hydrating a lipid with a
detergent solution or by drying both lipid and detergent from
an organic solution then adding an aqueous solution. The
detergent associates with the lipid, protecting the hydropho-
bic sections from interacting with the aqueous phase, and thus
micelles are formed rather than vesicles. The detergent is
removed from the micellar solution, using dilution by 10 to
100 fold, dialysis, column chromatography or adsorption, to
form the vesicles (6,7,12). Despite dilution being the simplest
method for detergent removal, the disadvantage is that the
ﬁnal concentration of liposomes in the solution is low and
entrapment of any hydrophobic compounds is poor. The
detergent also remains in the formulation and should be
removed via other methods. The size and homogeneity of
liposomes produced using detergent depletion are based on
the rate at which the detergent is removed and the initial ratio
of detergent to phospholipid (6). The method is very time
consuming and equilibration of the micelles can be a slow
process. Another potential disadvantage of the process is that
the methods used to remove the detergent may also remove
any other small hydrophilic compounds.
Injection Methods
The ethanol and ether injection methods involve the
dissolution of the lipid into an organic phase, followed by the
injection of the lipid solution into aqueous media, forming
liposomes. The ethanol injection method was ﬁrst described
in 1973 by Batzri and Korn (13). The ﬁne needle used to
inject the lipid solution disperses the ethanol and, conse-
quently, the phospholipid evenly in the aqueous media. The
ethanol injection method is a simple method, but some lipids
are poorly soluble in ethanol and heterogeneous liposomes
are formed if adequate mixing is not achieved. Since the
ethanol is injected directly into the aqueous media, residual
solvent levels can be a concern unless post-formation removal
is carried out.
The ether injection method differs from the ethanol
injection method since the ether is immiscible with the
aqueous phase, which is also heated so that the solvent is
removed from the liposomal product (14,15). The lipid-ether
solution is injected slowly into the aqueous media and large
unilamellar vesicles (LUVs) are formed. An advantage of the
ether injection method compared to the ethanol injection
method is the removal of the solvent from the product,
enabling the process to be run for extended periods forming a
concentrated liposomal product with high entrapment efﬁ-
ciencies. However, the slow injection means that it is a
lengthy process. It has been suggested that injecting the ether
solution at a rate faster than 0.2 ml/min. can cause cooling of
the aqueous media due to evaporation and that pre-evapora-
tion of ether can cause nozzle blockages and the formation of
multilamellar vesicles (MLVs) (6).
The ethanol injection method was used to prepare a
camptothecin analogue (Gimatecan, an anti-cancer drug)
liposome formulation (16). The concentration of the drug in
the aqueous phase was increased by multiple injections of
solution. The method is rapid, simple and reproducible for
production of a ready-to-use liposome suspension. The
particle size of liposomes produced by this method was a
function of lipid nature and concentration, the drug to lipid
ratio and the organic solvent and aqueous phase composition.
Fig. 1. A representation of the structure of a liposome, illustrating a
lipid bilayer surrounding an aqueous core with stabilising polymer
attached to the lipid surface
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allowed in situ preparation of liposome formulations with a
large concentration of drug without altering the narrow size
distribution. The major issue in the multiple injection method
is the amount of ethanol in the ﬁnal formulation and post-
formation processing (such as ultraﬁltration) may be required
to remove ethanol residue from the liposomal product.
Recent Modification Using an Inkjet. The inkjet method
is a modern variation on the ethanol injection method and
was developed by Hauschild et al.( 17) for liposome
formation with excellent control on particle size and high
potential for scaling up. An inkjet printer was used to inject a
phospholipid solution into water, producing small unilamellar
vesicles (SUVs) with diameters in the range of 50–200 nm,
narrow size distribution and efﬁcient encapsulation of drugs
into vesicles. Droplets with volumes in the range of picolitres
were formed with high reproducibility using commercially
available printers and cartridges.
Alcohol injection has been developed by two pharma-
ceutical companies: Alza and Polymun (18). Uniform lip-
osomes are then produced using extrusion by the Alza
Company and using a cross-injection module by Polymun.
The alcohol injection method is a simple and a low energy
process, however there are still issues associated with
liposome stability due to residual solvent (18).
Reverse Phase Evaporation Method
The reverse-phase evaporation (REV) process was ﬁrst
described by Szoka and Papahadjopoulos (19) and is based
on the formation of drops of water that are surrounded by lipid
and dispersed in an organic solvent, referred to as inverted
micelles. The technique is carried out by dissolving the lipids in
an organic solvent, adding a small volume of aqueous phase,
then sonicating the solution to produce inverted micelles. The
organic solvent is removed using a rotary evaporator and a
viscous gel forms. When sufﬁcient solvent has been removed,
the gel collapses and an aqueous suspension of vesicles forms.
A disadvantage of the reverse-phase evaporation process,
compared to some of the other conventional techniques, is that
the compound to be encapsulated within the vesicles is in
contact with an organic solvent, therefore the process is not
suitable for fragile molecules such as peptides (7). It is possible
to capture 30–45% of the aqueous phase within REVs and at
optimal conditions, up to 65% entrapment may be achieved
(19). The fact that a large portion of the aqueous volume is
captured and a large aqueous space exists within the vesicle
suggests that large macromolecules may be able to be
encapsulated within REVs.
Emulsion Method
Emulsion methods for the production of liposomes
generally involve the formation of a water-in-oil emulsion
through the addition of a small amount of aqueous media to a
larger volume of immiscible organic solution containing the
phospholipid (6). The mixture is agitated to disperse the
aqueous media as tiny droplets throughout the organic
solvent and the lipid aligns itself into a monolayer at the
boundary between the organic and aqueous phases. The size
of the droplets is controlled by the agitation applied and the
amount of lipid present, since there must be sufﬁcient lipid to
surround the droplet or it may fuse with other droplets (6).
The water-in-oil emulsion is transformed into a liposomal
suspension through the formation of a double emulsion (20).
The organic solution containing the water droplets is added to
a large volume of aqueous media and agitated, producing a
water-in-oil-in-water emulsion. A lipid monolayer also forms
around the organic droplets producing aqueous cores sur-
rounded by two lipid monolayers that are separated by an
organic layer. Unilamellar liposomes with high entrapment of
the initial aqueous media can then be formed by the removal
of the organic solvent, for example, by passing a stream of
nitrogen through the double emulsion (20).
A technique has been presented by Kim and Martin (21)
for the production of multivesicular liposomes using a
variation to the double emulsion method. The lipid, solvent
composition and shaking time period are controlled so that
multiple water droplets become contained within a single
organic droplet in the double emulsion (6). Once the organic
solvent is removed, the droplets form multiple compartments
within a single lipid vesicle, usually 1–2 µm in diameter.
Multivesicular liposomes provide the potential to deliver
multiple compounds that are unstable when combined (6).
Post-Formation Processing
Multilamellar vesicles can be produced and then modi-
ﬁed after production to alter the size, lamellarity or homoge-
neity and produce liposome populations with a speciﬁc size or
property. The most common methods for post-formation
processing are sonication, extrusion and high pressure
homogenization (6,7). A mechanical force is used to disrupt
the large multilamellar vesicles into small membrane patches
that ultimately form small unilamellar vesicles. For example,
Takahashi et al.( 22) developed an efﬁcient process for the
preparation of liposomes using a mechanochemical method.
In this technique liposomes were formed by dispersing
lecithins into deionised water using a homogeniser followed
by a microﬂuidiser at 1,000 bar for 5 min. Liposomes with
particle size of 100 nm were formed from the combination of
the homogeniser and microﬂuidiser with 80% drug loading
efﬁciency (22). The aforementioned methods are generally
size reduction techniques; however, as the liposomes are
processed the lamellarity and heterogeneity are also de-
creased. Incorporation compounds can also be encapsulated
within pre-formed liposomes through the use of remote
loading, where a pH, ion or proton gradient is induced across
the lipid membrane (23,24).
The conventional methods for liposome formation can
produce vesicles with diameters ranging from 20 nm to
several microns. Fan et al. (25) compared various liposome
preparation methods such as thin ﬁlm evaporation (Bangham
method), sonication, reverse phase evaporation, melting and
freezing-thawing. The highest encapsulating efﬁciency of
liposomes for salidroside was achieved by freezing-thawing,
followed by thin ﬁlm evaporation, reverse phase evaporation,
melting and then sonication. However, liposomal systems
prepared by sonication, melting, and reverse phase evapora-
800 Meure, Foster and Dehghanition displayed better dispersivity. Furthermore, salidroside
liposomes prepared by melting had a better physicochemical
stability (26).
Conventional methods are not suitable for processing
fragile molecules because of the exposure to volatile organic
solvents, detergent, sonication, or high shear homogenisation.
The signiﬁcant drawbacks of conventional preparation methods
include being generally complex, time consuming, not easily
scalable for mass production and there are difﬁculties in
achieving high encapsulation efﬁciencies. Toxic solvent residue
in the product is a signiﬁcant disadvantage due to the cost of
handling and removing solvents. Recently, unique methods
were developed for producing liposomes to minimize the issues
inherent in conventional liposome production techniques.
RECENT METHODS DEVELOPED
FOR THE SYNTHESIS OF LIPOSOMES
Freeze Drying of Monophase Solutions
Li and Deng (18) recently designed a freeze drying of
monophase solution method for formation of dry liposomes
that can be stored for a long time in a sealed container. The
process involved dissolving a phospholipid in t-butyl alcohol
and water–sucrose to form an isotropic monophase solution
and then freeze drying the solution. The freeze drying stage
was performed by ﬁrst freezing the sample at −40°C for 8 h,
followed by drying at this temperature for 48 hours and
ﬁnally drying the product at 25°C for 10 h, which is very time
consuming.
Li and Deng observed that the size and polydispersity of
liposome particles were decreased by increasing the sucrose
concentration. This effect may result from enhancing the
viscosity of sucrose solutions by increasing the concentration,
which inhibits the appearance of large solid t-butyl hydrate,
consequently forcing the formation of lipid-rich minidomains
(18). Furthermore, sucrose might prevent the fusion of
different minidomains during the drying process and in dry
status. The particle size of liposomes fabricated by this freeze
drying method was within 100 to 200 nm, which was
dramatically smaller and more uniform than the micron range
of liposomes produced previously using a t-butyl alcohol-
water mixture in the absence of sucrose (18). The Li and
Deng method can be used for both lipophilic and hydrophilic
drugs; however, the t-butyl alcohol–water system without
sucrose was used only for lipophilic drugs that are soluble in
t-butyl alcohol.
Microﬂuidic Channel Method
Jahn et al.( 26) developed a microﬂuidic method for
controlled liposome formation. Rectangular microﬂuidic
channels with a depth of 100 µm and a width of 46 or
64 µm were fabricated in a silicon wafer, as shown in Fig. 2.
Nanoports were bonded to the backside of the silicon wafer
and were connected to a syringe via a 254 µm capillary tube.
A lipid solution was injected into the central channel of the
microﬂuidic network while aqueous solutions passed into the
side channels, intersecting with the central channel. Lip-
osomes can be formed as different shear forces are generated
at the liquid interfaces by the changing ﬂow rate ratio. The
process involves a stream of lipid dissolved in alcohol passing
between two aqueous streams in a microﬂuidic channel, with
mixing occurring at the liquid interfaces and thus liposomes
forming. The laminar ﬂow in the channels enables control
over the diffusive mixing and thus the size and size
distribution of the liposomes can be manipulated through
adjusting the ﬂow conditions. Jahn et al.( 26) demonstrated
that monodispersed liposomes can be produced by adjusting
the ﬂow rates of the phospholipid and water solutions in
microchannels. Decreasing the sample stream width to
micrometer length scales allows for intimate mixing and
uniform conditions for formation of liposomes with a mean
geometric radius of 29 nm. Liposome self assembly by this
microﬂuidic method can be used for drug encapsulation
immediately prior to use, hence eliminating shelf life limi-
tations of the current liposome preparation techniques (26).
Membrane Contactor Method
Charcosset et al.( 27) designed a new process for solid
lipid nanoparticle formation that consisted of a membrane
contactor, which can be used for large scale production of
liposomes. In this method, a lipid phase was pressed at
temperatures above the melting point of the lipid through a
membrane with a speciﬁed pore size. Nitrogen gas at
pressures below 6 bar was sufﬁcient for passing the molten
phase through the membrane. Solid lipid nanoparticles with
particle size between 70 and 215 nm were formed and
collected by recirculation of a cold stream of aqueous phase
inside the membrane module. The advantages of this new
process are its simple design, the control of the solid-lipid
nanoparticle size by tuning the process parameters and its
scaling-up abilities (27).
Heating Method
A heating method developed by Mozafari to produce
liposomes involves the hydration of a phospholipid in an
aqueous solution containing 3 vol% glycerol and increasing
the temperature to 60°C or 120°C (8). Glycerol is utilized
since it is a water soluble and physiologically acceptable
chemical with the ability to act as an isotonising agent and
Fig. 2. Schematic diagram of the microﬂuidic channel used for
liposome formulation by Jahn et al.( 26)
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coagulation and sedimentation. No degradation of lipid was
reported for liposomes fabricated by the heating method and
no need for sterilisation as high temperature was used in this
technique. A drug was incorporated into liposomes using the
heating method by adding the drug to the solution at different
stages: 1) at the beginning; 2) when the temperature was
above the transition temperature of the lipids; and 3) at
ambient temperature after liposome preparation, for heat
sensitive materials such as DNA (8).
Dense Gas Techniques
Dense gas processes have been developed for the produc-
tion of liposomes in order to eliminate the issues involved in
conventional preparation. The term dense gas is a general
expressionusedtorefertoasubstanceintheregionsurrounding
the critical point. The phase diagram for a pure component is
depicted in Fig. 3 and shows the liquid, gas and supercritical
ﬂuid regions meeting at the critical point. Dense gases possess
solvent power similar to that of liquids along with mass
transport properties similar to those of gases. The unique
properties of dense gases have been exploited to replace many
organic solvents and enable improved processing techniques,
in particular separation, puriﬁcation and size reduction pro-
cesses. The most widely used dense gas is carbon dioxide since
it is non-ﬂammable, non-toxic, non-corrosive, inexpensive,
environmentally acceptable and has easily accessible critical
parameters of 31.1°C and 73.8 bar. The low critical tempera-
ture of CO2 means that a low energy input is required for
dense gas processing and the solvent is suitable for use with
thermally labile materials. The solvent can be easily recovered
after processing by simply returning to atmospheric pressure.
Dense gas processing can provide sterile operating
conditions and one-step production that can alleviate the
current liposome sterilisation issues (28,29). Currently, steri-
lised liposomes are formed by the use of sterilised solutions
and equipment during liposome manufacturing, which is time
consuming (30,31). Many other sterilisation methods are
unsuitable since liposomes are thermally labile and hydro-
lysed by γ-radiation. Sterilisation methods that involve
chemicals or heating can also release the encapsulated
material. Filtration is a non-destructive liposome sterilisation
method, however it is very time consuming and not efﬁcient
for removing viruses or bulk production.
Supercritical Fluid Injection and Decompression Method
The ﬁrst dense gas techniques for the formation of
liposomes, referred to as the injection and the decompression
methods, were described by Castor and Chu in 1994 (32). In
the injection method, a mixture of lipid, organic co-solvent
and compressed gas is injected through a nozzle into an
aqueous solution. Alternatively, the decompression method
involves a mixture of lipid, organic co-solvent, compressed
gas and aqueous solution being decompressed through a
nozzle to form liposomes. A simpliﬁed representation of the
apparatus used in the injection and decompression methods is
given in Fig. 4. The major distinction between the processes is
the incorporation of the aqueous solution. In the injection
method the compressed phase is sprayed into water, whereas
in the decompression method, the aqueous phase is incorpo-
rated into the compressed phase, which is sprayed into air.
The rate of depressurisation inﬂuences the size of the
liposomes formed. Castor and Chu claim the injection and
decompression processes are capable of producing sterile,
pharmaceutical grade liposomes of a pre-determined size that
have a narrow particle size distribution and are substantially
solvent free (30). It is preferred that any pharmaceutical
incorporated is not shear sensitive when applied to the
decompression method (31). Conversely, the injection meth-
od does not subject the materials to high shear forces and so
is suitable for fragile drug molecules. A homogenisation or
size-reduction method was also described by Castor and Chu
through depressurising a mixture of pre-formed MLVs and
compressed ﬂuid so as to separate the ﬂuid and produce
liposomes of a uniform size (30,32,33).
In 2005, Castor (34) reported the production of small
uniform liposomes (or phospholipid nanosomes) using pro-
cesses similar to the injection and decompression methods
and referred to them as the SuperFluids phospholipid nano-
some (SFS-CFN) manufacturing process. Castor states that a
key ingredient of the process is the ability of the dense gas to
dissolve the materials and consequently utilizes co-solvents
and a circulation loop to ensure the solutes are completely
dissolved prior to depressurisation. A number of variations
on the operation of the process were investigated based on
the type of incorporation compound and its subsequent
solubility in the aqueous or dense gas phase. A hydrophilic
protein (cytochrome-C) and hydrophobic model drugs (pac-
litaxel, camptothecin and betulinic acid) were encapsulated
within the liposomes and in vitro and in vivo testing was
conducted on the product (34).
The data presented by Castor suggests that the SFS-CFN
experiments produced liposomes in the size range 100 nm and
4 µm, but more commonly less than 200 nm at 60°C and
280 bar (34). Liposome formulations produced by this
method were stable, in terms of particle size distribution, for
6 months when stored at 4°C. The in vivo study of the
liposomes containing paclitaxel showed that the formulation
had a signiﬁcantly greater effect on the cancer cells than the
conventional therapeutic formulation and may therefore
provide improved treatment of breast cancer (34).
Fig. 3. Pressure–temperature diagram for a pure component
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solvents and elevated temperatures and pressures to achieve
solubilisation of the raw materials for liposome processing.
The use of solvents such as chloroform is eliminated in the
SFS-CFN process, however the processing time, temperature
and pressure (350 bar) required for the process are still
high (34).
Supercritical Fluid Liposome Method
Frederiksen et al. described the supercritical liposome
method in 1994, which is similar to the injection method
developed by Castor and Chu, and produced SUVs with
particle size between 20 and 50 nm (28,35,36). The process is
depicted in Fig. 5 and involves the dissolution of phospholipid
and cholesterol into supercritical carbon dioxide at 60°C and
250 bar using 5–7% ethanol as a co-solvent. The lipid and
cholesterol were dissolved after being placed in a cartridge
through which repeated cycles of carbon dioxide/ethanol was
passed. The recycling system was used to dissolve both the
lipid and cholesterol, which have different solubilities in the
dense gas phase, such that homogeneous liposomes could be
generated. The solution was then rapidly expanded into an
aqueous phase containing the hydrophilic compound to be
entrapped.
The foam formation that may appear in the process upon
depressurisation of the high pressure solution directly into the
aqueous phase was eliminated by expanding and simulta-
neously contacting the pressurised solution with the aqueous
solution in a capillary prior to dilution in a low-pressure
recycling system. An encapsulation efﬁciency of 15% was
achieved using this method (35). The formation of the
liposomes in the capillary is a signiﬁcant difference between
the supercritical liposome method and the injection method.
In addition to SUVs, a small fraction of large MLVs (250 nm)
were also formed (35). The dimensions of the capillary within
which the liposomes are formed affects the encapsulation
efﬁciency and the size of the liposomes, therefore the internal
surface area of the capillary should be minimized to achieve a
high encapsulation volume. The amount of ethanol required
to produce liposomes by the ethanol injection method was 15-
fold more than that required for the supercritical liposome
method (35). However, the encapsulation efﬁciency was 20%
for the supercritical liposome technique, which was 50%
lower than that achieved using conventional liposome forma-
tion techniques. It is believed that the lower encapsulation
efﬁciency is compensated for by the elimination of the
requirement for toxic solvents, the decreased organic solvent
consumption and the convenient scaleable method.
Bridson et al. also studied the production of liposomes
using a method similar to Frederiksen et al.( 35–37). The
focus of the study was on investigating the entrapment
capabilities and the effects of process parameters on the
product obtained. Bridson et al. produced liposomes with
between three and ﬁve bilayers and an average diameter of
200 nm, which is signiﬁcantly different to the 20 – 50 nm
SUVs reported by Frederiksen et al. The authors concluded
that liposomes with a broad particle size distribution were
produced and post-formation processing may be required to
improve the product.
Supercritical Reverse Phase Evaporation Process
In the Supercritical Reverse Phase Evaporation (scRPE)
method developed by Otake et al., the lipid, organic co-
solvent and compressed gas are combined in a stirred,
variable volume cell at a temperature above the lipid phase
transition temperature, as depicted in Fig. 6 (29). An aqueous
solution is then slowly introduced to the cell. The pressure is
reduced by the release of the compressed gas and liposomes
are formed. The principle of the scRPE method is similar to
the decompression method described by Castor and Chu
since the lipid, aqueous phase, dense gas and modiﬁer are
combined and then depressurised to form liposomes. The
difference is that the depressurisation generally occurs in the
decompression method by spraying the solution through a
nozzle, whereas in the scRPE method the depressurisation
occurs by the release of the dense gas from a variable volume
cell containing the materials. The process described by Otake
et al. is physically simpler than Frederiksen et al.’s supercrit-
ical liposome method and requires less carbon dioxide, but
the mechanism of formation is more complicated (29,35,36).
The liposomes produced by scRPE were also signiﬁcantly
larger than those produced by Frederiksen et al.( 29,35,36).
In the scRPE method, a water/CO2 microemulsion forms
as water is introduced into the cell, then when more water is
introduced the cell becomes opaque as a macroemulsion
forms, based on reverse micelles of lipid (29). A transition
occurs from a water/CO2 emulsion to a CO2/water emulsion
with increasing amounts of aqueous phase. Liposomes may
then be formed as the CO2 is evaporated from the aqueous
phase upon depressurisation. Attempts were made to pro-
duce liposomes when some solid lipid was present, rather
than completely dissolved lipid, however the trapping efﬁ-
ciencies achieved were extremely low (29). The lipids used
have very low solubility in carbon dioxide; therefore the
organic co-solvent is incorporated to improve the solubility of
the lipid in the dense gas phase. Although organic co-solvent
is used in the scRPE method, non-toxic solvents can be
Fig. 4. Simpliﬁed schematic of the apparatus used in the Decom-
pression and Injection method (30)
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et al., the optimum concentration of ethanol added was 7 wt%
when high temperatures and pressures were used (60°C and
200 bar) (29).
Otake et al. formed ellipsoidal LUVs that ranged in size
from 100 nm–1.2 µm and the vesicles became spherical as the
size was decreased (29,38). It was suggested that the
ellipsoidal shape is caused by the lower stability of the LUVs
in comparison to spherical MLVs. A high trapping efﬁciency
was achieved for encapsulation of both water-soluble (glu-
cose) and oil-soluble (cholesterol) materials (29). The oil-
soluble substance was present with the lipid and the water-
soluble substance introduced with the aqueous phase. The
product from the scRPE method was compared to MLVs,
LUVs and giant unilamellar vesicles (GUVs) formed using
conventional methods (29,39). The scRPE method achieved a
trapping efﬁciency comparable to the conventional LUVs,
lower than the GUVs and higher than the MLVs. scRPE has
been carried out using a semi-batch apparatus that is capable
of producing 50 cm
3 of liposomal product in 100 min (40).
Water-soluble vitamin C and oil-soluble cholesterol, ceramide
3 and a vitamin A derivative were encapsulated in liposomes
using this technique.
Otake et al.( 41) recently developed a new method
known as the improved supercritical reverse phase evapora-
tion (ISCRPE) technique to avoid the use of organic solvent
in liposome formation and enhance the stability and the drug
loading efﬁciency. In this method, the inhomogeneous
mixture of a phospholipid powder and aqueous solution was
prepared using a stirrer, the solution was then pressurised by
CO2 to form a CO2/water emulsion at 60°C and 200 bar, and
after 40 min the system was depressurised to generate
liposomes. Eliminating ethanol from the scRPE process
decreases the liposome disruption and enhances its trapping
efﬁciency. The rate of phase inversion during depressurisation
has an impact on the properties of the liposomes. The
trapping efﬁciency and the size of the liposome were
increased at slow depressurisation rate, as a result of
decreasing the surface-to-volume ratio of particles with the
same amount of phospholipid. Otake et al.( 41) also observed
that the trapping efﬁciency was promoted by increasing the
phospholipid chain length and addition of a double bond into
the main chain.
The liposome formulation prepared by the ISCRPE
technique remained stable after 30 days, while products from
the Bangham and scRPE methods were not stable after 6 h
and 14 days, respectively (41). It was also found that the
stability of liposomes produced from ISCRPE with CO2 was
higher than with N2, possibly due to the static repulsion of the
Fig. 5. Simpliﬁed schematic of the apparatus used in the supercritical liposome method (39)
Fig. 6. Simpliﬁed representation of the apparatus used in the scRPE
method (33)
804 Meure, Foster and Dehghanicarbonic acids incorporated into the bilayer membrane. The
addition of chitosan to the liposomal formulation in the
ISCRPE method did not affect its stability (30 days) and a
trapping efﬁciency of 17% was achieved (42).
Other Dense Gas Processes
Work has been carried out on the formation of lipid
particles, as a step towards liposome formation, using dense
gas technology. Magnan et al. micronized soy lecithin using
two dense gas processes, the supercritical anti-solvent (SAS)
precipitation process and rapid expansion of supercritical
solutions (RESS) process, and claimed that future work
would deal with the formation of liposomes through the
dispersion of the ﬁne phospholipid particles in water, which
could be conducted in the same vessel without opening
(43,44). In the SAS process, ethanol was used to dissolve
the soy lecithin and carbon dioxide was used as the anti-
solvent for precipitation. Fine, but aggregated, phospholipid
particles were formed that ranged in size from 1–40 µm and
contained no residual solvent (43). The higher the percentage
of the phosphatidylcholine ins o yl e c i t h i n ,t h e nb e t t e r
solubility and yield could be achieved.
The RESS process uses a dense gas, with or without co-
solvents such as ethanol, to solubilise the lipid before
depressurisation to form microparticles. The RESS process
was not successful for liposome formulation, due to the
inability to separate the lipid particles from the co-solvent
upon depressurisation, utilising CO2 as an anti-solvent for
micronization of liposomes from ethanol solution was efﬁ-
cient (44). Further information about phase behaviour, mass-
transfer kinetics as well as hydrodynamic considerations are
required for liposome formulation by the SAS and RESS
techniques. It is clearly evident, however, that there is a great
amount of interest in lipid and liposome processing using
dense gas techniques.
More recently, Kunastitchai et al. micronized phosphatidyl-
choline, cholesterol and miconazole using the aerosol solvent
extraction system (ASES), a process essentially identical to the
S A Sp r o c e s s ,a n dr e f e r r e dt ot h ep r o d u c ta sl i p o s o m e si nad r y
and reconstitutable form (45,46). Miconazole was used as the
model drug and poloxamer 407 was incorporated in some
experiments as a surfactant. A methanol and methylene
chloride mixture was used to solubilise the components prior
to processing, however 3–4 h of washing was required post-
formation to minimize the amount of residual solvent left in the
product. Aggregates of microparticles were produced that
ranged in size from a few microns to 40 µm. The particles were
added to phosphate buffer at 55°C and agitated by vortex
mixing to hydrate the microparticles and produce liposomes.
Fig. 7. Schematic diagram of the apparatus used in the DESAM process (55)
Fig. 8. Liposomes produced by a new rapid, simple, one-step dense
gas liposome formation process, DESAM (55)
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powders by using compressed carbon dioxide as an anti-
solvent for precipitating lipid from ethanol solution (37). In
the SAS and ASES processes, the lipid-alcohol solution is
sprayed via a nozzle into a chamber containing the dense gas
anti-solvent. However, Bridson et al. injected the lipid-alcohol
solution into a T-piece through which the dense gas was
ﬂowing then collected the micronized lipid downstream in a
ﬁlter. The phospholipid powder was hydrated by agitation in
an aqueous solution at a temperature above the glass
transition temperature of the lipid, forming liposomes of
approximately 5 μm diameter. It is clearly evident that the
size of the liposomes produced by ﬁrstly micronizing lipid was
dramatically larger than liposomes produced by most other
dense gas formation techniques.
The disadvantage of processes that produce micronized
lipid as an initial step in liposome production is the
requirement for multiple stages to achieve the ﬁnal liposomal
product. However, Kunastitchai et al.( 45)s u g g e s tt h a t
producing lipid particles instead of liposomes is beneﬁcial
since the stability of liposomes during storage can be an issue
and lipid particles can be rehydrated to liposomes prior to
use. Therefore, the liposome production is still being con-
ducted in two stages, however there is a time delay between
the stages such that the liposomes are only formed immedi-
ately prior to use.
Table I. Advantages and Disadvantages for Large Scale Production using the Major Conventional Liposome Formation Methods
Conventional Methods Advantages Disadvantages
Bangham Simple process Large amount of organic solvent,
requires vigorous agitation, large vesicles with
no control on particle size, time consuming,
sterilisation issue
Detergent depletion Simple process, homogenous product,
control of particle size
Large amount of organic solvent,
detergent residue in the product,
time consuming, poor entrapment efﬁciency,
low yield, sterilisation issue
Ethanol/ether injection Simple process Organic solvent residue, nozzle
blockage in ether system due to
pre-evaporation, time consuming,
sterilisation issue
Inkjet injection Simple process, control on particle size and homogeneity,
high potential for scale-up and encapsulation efﬁciency,
low energy process
Organic solvent residue, low drug
stability, sterilisation issue
Reverse phase evaporation Simple design, reasonable encapsulation efﬁciency Not suitable for encapsulation of fragile
molecule due to large quantity of
organic solvent use, time consuming,
sterilisation issue
Emulsion Simple, potential to fabricate multivesicular liposome
for delivery of multiple compounds that are not
stable in combination
Large amount of organic solvent, requires
vigorous agitation, sterilisation issue
Table II. Advantages and Disadvantages for Large Scale Production using the Major Advanced Liposome Formation Methods
Advanced Methods Advantages Disadvantages
Freeze drying of monophase solution Feasible to process dry liposome, low organic
solvent residue, increased stability
Time consuming, sterilisation issue
Microﬂuidic channel Control of particle size, allows production of vesicles
with diameter up to 29 nm
Not suitable for bulk production,
organic solvent use, issues with
availability and high cost of
microﬂuidic channels
Membrane contactor Simple process for controlled particle size, no use
of organic solvent
High temperature, membrane
blockage and sterilisation issues
Heating Simple, no organic solvent use, in situ sterilisation,
scale-up possible
Use of high temperature that




Control of particle size, possible in situ sterilisation,
low organic solvent consumption
High capital cost, low yield, high
pressure up to 350 bar used
Supercritical liposome method Possible in situ sterilisation, low organic solvent consumption High capital cost, low yield and
encapsulation efﬁciency, high
pressure up to 250 bar used
Improved/ supercritical reverse
phase evaporation
No need for using nozzles, one-step closed vessel
production, low organic solvent consumption, rapid process,
scale-up potential, enhance stability by eliminating ethanol
High capital cost, high pressure
up to 200 bar used
Depressurisation of an Expanded
Solution into Aqueous Media
Simple and rapid process, scale-up potential, low temperature
process, in situ removal of organic solvent residue
High capital cost
806 Meure, Foster and DehghaniKunastitchai et al.( 46) studied the stability of both the
lipid-drug particles and reconstituted liposomes by examining
the drug loading initially and months later. The stability
showed varying trends depending on composition, storage
temperature and pH of hydration medium. The data pre-
sented by Kunastitchai et al. suggests that the micronized
particles and the liposomes hydrated at pH 7.2 were generally
stable for the length of the stability study (3–5 months), based
on drug loading. The particle size distribution also showed
good stability over 3 months for the reconstituted liposomes
when a pH 7.2 hydration solution was used. Lastly, Kunas-
titchai examined in vitro cellular uptake of the liposomes by
incubation with human lymphocytes and claimed that the
liposomes appear to be substantially internalised, possibly
leading to degradation of the structure and release of the
drug (46).
During the last few years a few patents have been ﬁled
using dense gas technology for liposome formulation that
include minimal or no organic solvents (47–54). Wada and
Motokui combined lipid, cholesterol, a lipid-polymer com-
pound and a water soluble agent with supercritical carbon
dioxide (52,53). The pressure was then reduced, releasing the
carbon dioxide, and the dispersion mixed with a higher
concentration solution of water soluble agent. The method
was used to encapsulate x-ray contrast agents within lip-
osomes. Ueda et al. used a dense gas emulsion process to
encapsulate photosensitizers or imaging, anti-cancer, or
antifungal agents in liposomes (47,51). The processes de-
scribed are similar to the scRPE method described earlier by
Otake et al.( 29). Ueda also encapsulated gas into liposomes
through using pressure difference (50).
Despite the clear advantages of dense gas liposome
production, there are also problems with the known processes
for liposome formation. The dense gas processes described to
produce liposomes directly generally require elevated pres-
sures of at least 69 bar (1,000 psi) and the conditions
commonly used are 200–300 bar and temperatures of 60°C.
Solubilising the materials in a dense gas and establishing the
appropriate conditions for solubilisation can also be a
complicated process. It is difﬁcult working with mixtures in
supercritical and near critical systems in conditions where
solid components of the mixture readily block nozzles and
other parts of the equipment used. An additional drawback is
that the existing dense gas processes for producing liposomes
do not provide a way for the co-solvent or modiﬁer that is
mixed with the dense gas to be removed from the system,
with the exception of the ISCRPE process. Therefore, the
presence of the solvent or modiﬁer in the liposomal product
becomes a contaminant and consequently a potential problem.
Accordingly, investigations have been carried out by the
authors to develop a process to form liposomes which utilizes
the advantages of dense gases without the disadvantages
described above. The rapid, one-step process (depicted in
Fig. 7) involves the depressurisation of expanded solution
into aqueous media (DESAM) and was used to produce
uniform liposomes and remove organic solution in situ (55).
In particular, the process was designed to utilize moderate
temperatures and pressures below 60 bar. The new method
needed to be both easily adaptable to a variety of incorpo-
ration compounds and easily scalable for mass production.
Liposomes with diameters generally between 50–200 nm have
been successfully produced, as shown in Fig. 8. The process
was also extended to the formation of sterically stabilised
liposomes.
Large Scale Liposome Fabrication
Various techniques have been developed for the bench
scale liposome formation, however the broad application of
liposomes in drug delivery is still impeded due to scale up
issues. The advantages and disadvantages, in regard to the
transition from lab to large scale operation, of the major
liposome processes described above are summarised in Table
I for conventional and in Table II for the recent advanced
methods. Liposome formation processes should be validated
according to Good Manufacturing Practice (GMP) protocols
prior to commercialisation. The validation of current methods
for liposome formation is challenging as there are still issues
in reproducible production of desired size vesicles, the use of
organic solvents in the process, stability of formulation,
multiple-stage processing and problems associated with
current liposome sterilisation. Liposomal drug formulations
have been increasingly used in clinical trials during the last
few years with many encouraging results. The outcome of the
clinical trials transferred liposome from laboratory to clinical
applications. It is therefore of particular importance to design
a process that is cost effective for production of liposomes in
large quantities for new drug formulations.
Wagner et al.( 56) presented a new scalable liposome
production scheme for the ethanol injection technique that
allowed production on a several litres scale. In this process a
cross-ﬂow injection module was used that allowed liposomes
to be manufactured regardless of production scale and no
mechanical forces were required to generate homogenous
liposomes. The size of liposome vesicles and encapsulation
rate were controlled by the lipid concentration at the injection
point, injection pressure and injection rate. The drug-lipo-
some formulation was ﬁrst optimized in a laboratory scale
and the scale-up was performed by changing the size of the
process vessel. Regardless of the advantages of this method
compared with other liposome formation techniques, there is
still the issue of residual ethanol in the ﬁnal product (56).
New, advanced technology, such as using microﬂuidic
devices and membranes, could be implemented for point-of-
care formulation preparation, thus eliminating stability limi-
tations on the product. The scale up of the aforementioned
processes will, however, rely on fabrication of low-cost
microﬂuidic devices and advances in membrane technology.
The dense gas techniques developed can address scale up
issues for liposome formulation, in particular enabling
production conducted in a totally enclosed single step. There
is also evidence that carbon dioxide can inactivate bacteria
and endotoxins, which is beneﬁcial in terms of GMP
regulations, but does not denature the bio-molecules (57–59).
CONCLUSIONS
Liposomes have wide potential in the pharmaceutical
industry, however companies are interested in using a low
cost, simple, one-step process that complies with GMP
restrictions. Many processes are under development to
address the major issues in liposome processing, enhance
807 Conventional and Dense Gas Techniques for the Production of Liposomesstability of the product and eliminate organic solvent usage.
Despite the drawbacks of conventional methods, large scale
liposome manufacture has been carried out using recent
advances in injection methods. The ISCRPE and DESAM
methods, as well as application of microﬂuid channels and
membranes, are promising in terms of process intensiﬁcation
(decreasing the processing steps, time, complexity) and
production of sterile, homogenous, stable liposomal formula-
tion products.
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